• Return to Headlines

Shares of Karyopharm Thera Has Risen Above Previous 52-Week High

By James Quinn

Shares of Karyopharm Thera (NASDAQ:KPTI) traded at a new 52-week high today of $18.87. Approximately 92,000 shares have changed hands today, as compared to an average 30-day volume of 225,000 shares.

In the past 52 weeks, shares of Karyopharm Thera have traded between a low of $6.27 and a high of $18.87 and are now at $18.73, which is 199% above that low price. Over the past week, the 200-day moving average (MA) has gone down 2.7% while the 50-day MA has advanced 2.4%.

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopham Therapeutics serves the healthcare industry throughout the United States and Germany.

Karyopharm Thera (NASDAQ:KPTI) is currently priced 5.5% above its average consensus analyst price target of $17.70. The stock should discover initial support at its 200-day moving average (MA) of $11.92 and subsequent support at its 50-day MA of $8.47.

SmarTrend recommended that subscribers consider buying shares of Karyopharm Thera on April 16th, 2018 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $14.01. Since that recommendation, shares of Karyopharm Thera have risen 31.5%. We continue to monitor KPTI for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: 52 week high/lows karyopharm thera

Ticker(s): KPTI